Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Nova Biomedical

Nova is a world leader in the development and manufacturing of whole blood, point-of-care and critical care analyzers... read more Featured Products: More products

Download Mobile App




Nova Biomedical Launches New BioProfile FLEX2 On-Line Autosampler

By LabMedica International staff writers
Posted on 03 Jan 2020
Nova Biomedical (Waltham, MA, USA) has launched the BioProfile FLEX2 On-Line Autosampler (OLS), a modular system that connects as many as 10 bioreactors to one FLEX2 analyzer for up to three weeks of walkaway, automated sampling, analysis, and feedback control of key cell culture analytes. More...
The FLEX2 measures up to 16 tests, including pH, gases, metabolites, osmolality, cell density, and cell viability.

Nova develops and manufactures state-of-the-art, whole blood point-of-care and critical care analyzers, as well as the most advanced instruments for cell culture monitoring in the biotechnology market. Nova’s biosensor technology is incorporated in its products ranging from handheld meters for glucose self- and point-of-care testing to critical care whole blood analyzers for the rapid measurement of over 20 analytes. Nova’s biotechnology-specific BioProfile line has pioneered comprehensive cell culture testing, providing over 16 critical cell culture tests with 12 unique instrument offerings for a broad range of cell culture applications.

Nova’s FLEX2 combines its MicroSensor Card chemistry technology with optical measurements and freezing point osmometry to offer an automated and comprehensive cell culture analyzer that eliminates chemistry sensor maintenance, increases analyzer speed, and reduces sample volume. With the OLS, FLEX2 uses a small sample volume of 5.6 mL for the 16-test assay to allow frequent sampling for this detailed look at culture performance. Up to 24 samples per day for each of 10 bioreactors can be analyzed in as fast as six minutes, with proven comparability to manual sampling. The OLS provides automated sampling, analysis, and feedback control of 10 bioreactors in as fast as one hour for chemistry results, with only 20 minutes needed for setup. The ability of OLS and FLEX2 to provide unaided capture of key cell culture attributes across 10 bioreactors saves hours of scientists’ time versus manual sampling and analysis, and eliminates after-hours cell culture monitoring.

“We are excited to launch the next addition to the BioProfile FLEX2 platform with the On-Line Autosampler. FLEX2 OLS represents the latest in cell culture automation technology and further demonstrates Nova’s leadership and history of innovation,” said Matt McRae, sales product line manager at Nova.

Related Links:
Nova Biomedical


Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gel Cards
DG Gel Cards
Rapid Molecular Testing Device
FlashDetect Flash10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.